RxDoctor Payments Data

Adam Schluterman

Optometrist · Fort Smith, ARNPI 1316102437

Payments from drug & device makers

$1,227in general payments, 2019–2025

Across 42 payments — averaging $29.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$325
  • Biotissue Holdings Inc.$192
  • Glaukos Corporation$146
  • Sun Pharmaceutical Industries Inc.$114
  • Oyster Point Pharma, Inc.$79
  • Johnson & Johnson Vision Care, Inc.$68
  • plus $304 from 10 others

What the payments were for

  • Food & beverage$1,227100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,227 in reported general payments places this provider in the 65th percentile of 442 optometrist providers in Arkansas.

See all optometrist providers in Arkansas

Medicare billing

Part B allowed, 2024
$206,461
Medicare patients
1,239
Services billed
2,749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine39$41,497
XiidraLifitegrast15$17,254
LumiganBimatoprost22$9,153
Latanoprost884$6,537
TobradexTobramycin/Dexamethasone14$3,680
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol26$2,803
Prednisolone Acetate75$2,561
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat199$2,474
SimbrinzaBrinzolamide/Brimonidine Tart13$2,416
Timolol Maleate257$2,175
Brimonidine Tartrate133$1,793
Fluorometholone23$1,427
Doxycycline Hyclate37$967
ValacyclovirValacyclovir Hcl12$964
Atropine Sulfate12$861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$325$50,65061 claims
Bausch & Lomb Americas Inc.Xiidra$42$17,25415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 442 optometrist providers in Arkansas.

Other optometrist in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →